Quarterly report · Q2
6523.TEDINET S100PICM
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥170.6bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥89.1bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥166.1bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥85.1bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥13.5bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥7.9bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥9.7bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.0bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥15.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥15.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.6bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥596.3bn | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥569.2bn | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥446.9bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥149.3bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥124.1bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥148.3bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥123.5bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥73.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥59.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥5.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥20.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥8.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥20.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥14.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥9.61 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.6 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥129.06 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.67 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥9.52 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥65.98 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥125.01 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥38.42 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 24.9% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 21.7% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥9.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥20.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥8.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥53.7bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥53.7bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥10.5bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥66.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥66.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥8.8bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥164.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥164.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥22.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 976
| Item | Context | Value | Unit |
|---|---|---|---|
| Comparative period end date | FilingDateInstant | 2021-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | - | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | - | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | - | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)KKR PHC Investment L.P.(常任代理人 株式会社三菱UFJ銀行) | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)ケイマン諸島、KY1-1104、グランドケイマン、ユーグランド・ハウス、私書箱第309(東京都千代田区丸の内2-7-1) | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)三井物産株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都千代田区大手町1-2-1 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)株式会社生命科学インスティテュート | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内1-1-1 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)パナソニックホールディングス株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)大阪府門真市大字門真1006番地 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)LCA 3 Moonshot LP(常任代理人 SMBC日興証券株式会社) | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口) | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)東京都港区浜松町二丁目11番3号 | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行(信託口) | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都中央区晴海一丁目8番12号 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)PHCホールディングス従業員持株会 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)東京都港区西新橋二丁目38番5号 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)JPモルガン証券株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内二丁目7番3号 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)BIBLIOTEKSGATEN 29 11435 STOCKHOLM SWEDEN(東京都千代田区丸の内2-7-1) | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | - |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |